Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MARCO CRISPR Activation Plasmid (h): sc-402692-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MARCO CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- MARCO CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by MARCO CRISPR Activation Plasmid (h) and MARCO CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the MARCO transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MARCO Antibody (F-3): sc-398053
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MARCO CRISPR Activation Plasmid (h) | sc-402692-ACT | 20 µg | $397.00 |
Human MARCO (macrophage receptor with collagenous structure) is a class A scavenger receptor predominantly expressed by macrophages and specialized dendritic cell subsets, where it mediates binding and internalization of a broad spectrum of polyanionic ligands, including bacterial components and environmental particles. By promoting non-opsonic phagocytosis and particle uptake, MARCO contributes to innate immune surveillance, antigen handling, and regulation of inflammatory signaling downstream of pattern recognition pathways. Altered MARCO expression or activity has been associated with dysregulated myeloid cell activation and tissue inflammation, and it is frequently studied in the context of pulmonary immune responses, infection biology, and tumor-associated macrophage phenotypes. As a surface receptor shaping myeloid–microenvironment interactions, MARCO is relevant for investigating host–pathogen interactions, immune cell trafficking, and inflammatory remodeling.
MARCO CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous MARCO expression without altering the underlying DNA sequence.
MARCO CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the MARCO locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the MARCO transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous MARCO expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native MARCO locus and enabling the study of MARCO-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of MARCO pathway restoration in tumor cells with silenced or reduced MARCO expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.